IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma

PURPOSE: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with a median survival of 15–20 months. Numerous approaches and novel therapeutics for treating GBM have been investigated in the setting of phase III clinical trials, including a recent analysis of the immune checkpoin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Ladomersky, Erik, Zhai, Lijie, Lenzen, Alicia, Lauing, Kristen L., Qian, Jun, Scholtens, Denise M., Gritsina, Galina, Sun, Xuebing, Liu, Ye, Yu, Fenglong, Gong, Wenfeng, Liu, Yong, Jiang, Beibei, Tang, Tristin, Patel, Ricky, Platanias, Leonidas C., James, C. David, Stupp, Roger, Lukas, Rimas V., Binder, David C., Wainwright, Derek A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984675/
https://ncbi.nlm.nih.gov/pubmed/29500275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3573
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge